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Abstract
Background: It has been suggested that p300 participates in the regulation of a wide range of cell biological
processes and mutation of p300 has been identified in certain types of human cancers. However, the expression
dynamics of p300 in hepatocellular carcinoma (HCC) and its clinical/prognostic significance are unclear.
Methods: In this study, the methods of reverse transcription-polymerase chain reaction (RT-PCR), Western blotting
and immunohistochemistry (IHC) were utilized to investigate protein/mRNA expression of p300 in HCCs. Receiver
operating characteristic (ROC) curve analysis, spearman’s rank correlation, Kaplan-Meier plots and Cox proportional
hazards regression model were used to analyze the data.
Results: Up-regulated expression of p300 mRNA and protein was observed in the majority of HCCs by RT-PCR and
Western blotting, when compared with their adjacent non-malignant liver tissues. According to the ROC curves,
the cutoff score for p300 high expression was defined when more than 60% of the tumor cells were positively
stained. High expression of p300 was examined in 60/123 (48.8%) of HCCs and in 8/123 (6.5%) of adjacent non-
malignant liver tissues. High expression of p300 was correlated with higher AFP level, larger tumor size, multiplicity,
poorer differentiation and later stage (P < 0.05). In univariate survival analysis, a significant association between
overexpression of p300 and shortened patients’ survival was found (P = 0.001). In different subsets of HCC patients,
p300 expression was also a prognostic indicator in patients with stage II (P = 0.007) and stage III (P = 0.011).
Importantly, p300 expression was evaluated as an independent prognostic factor in multivariate analysis (P =
0.021). Consequently, a new clinicopathologic prognostic model with three poor prognostic factors (p300
expression, AFP level and vascular invasion) was constructed. The model could significantly stratify risk (low,
intermediate and high) for overall survival (P < 0.0001).
Conclusions: Our findings provide a basis for the concept that high expression of p300 in HCC may be important
in the acquisition of an aggressive phenotype, suggesting that p300 overexpression, as examined by IHC, is an
independent biomarker for poor prognosis of patients with HCC. The combined clinicopathologic prognostic
model may become a useful tool for identifying HCC patients with different clinical outcomes.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world and the third leading cause of
cancer mortality [1]. It is among the top three causes of
cancer death in the Asian Pacific region due to the high
prevalence of chronic hepatitis B virus and hepatitis C
virus infections, and recently its incidence in the United
States and in Western Europe has been increasing [2,3].
Despite new therapies and attempts for early detection
of primary HCC, the long-term survival of HCC patient
remains poor. Surgery is considered as one of the stan-
dard curative treatments for HCC if the tumor is resect-
able [4]. However, the prognosis of HCC patients with
the same clinical stage often differs substantially in spite
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mostly unexplained. Thus, a large amount of investiga-
t i o n so nH C Ch a v ef o c u s e do nt h ed i s c o v e r yo fs p e c i f i c
molecular markers that could serve as reliable prognos-
tic factors. To date, however, the search for specific
molecules in HCC cells that have clinical/prognostic
value remains substantially limited.
Recently, it has been reported that p300, a member of
the histone acetyltransferase family of transcriptional
coactivator, is found to play a variety of roles in the
transcription process and catalyzes histone acetylation
through its histone acetyltransferase activity [5,6]. Tran-
scriptional coactivator p300 has been shown to partici-
pate in the regulation of various cellular processes such
as proliferation, differentiation, apoptosis, cell-cycle reg-
ulation and DNA damage response [7]. A tumor sup-
pressor role of p300 has been identified in certain types
of human cancers, including breast, colorectal and gas-
tric carcinoma [8,9]. However, several studies suggest
that transcriptional coactivator p300 is a positive regula-
tor of cancer progression and related to tumorigenesis
of various human cancers [10,11]. The translational co-
activator p300 was found to be involved in the integrin
beta-1-mediated histone acetylation and p21 transcrip-
tional activation in HCC [12]. In addition, Wang et al
[13] suggested that a direct role of phosphor-CREB in
p300 and Brg I recruitment to the Hulc promoter led to
the activation of epigenetic markers and chromatin
remodeling at the same location in hepatic cancer cells.
It has also been reported that p300 expression correlates
with nuclear alterations of tumor cells and contributes
to the growth of prostate carcinoma and is a predictor
of aggressive features of this cancer [14,15].
Up to date, the clinicopathologic/prognostic implica-
tion of p300 in HCC has not been explored. In this
study, reverse transcription-polymerase chain reaction
(RT-PCR), Western blotting, immunohistochemistry
(IHC) and tissue microarray were utilized to examine
the distribution and frequency of p300 expression in our
HCC cohort and adjacent non-malignant liver tissues. In
order to avoid predetermined cutpoint, receiver operat-
ing characteristic (ROC) curve analysis was employed to
define the cutoff score for high expression of p300. In
addition, the correlation between p300 expression and
cell proliferation levels in our HCCs was analyzed using
the Ki-67 assessment marker.
Methods
Patients and tissue specimens
In this study, the paraffin-embedded pathologic speci-
mens from 123 patients with HCC were obtained from
the archives of Department of Pathology, Sun Yat-Sen
University Cancer Center, Guangzhou, China, between
July 2005 and May 2008. The cases selected were based
on distinctive pathologic diagnosis of HCC, undergoing
primary and curative resection for tumor without preo-
perative anticancer treatment, availability of resection
tissue and follow-up data. These HCC cases included
107 (87.0%) men and 16 (13.0%) women, with mean age
of 47.7 years. Average follow-up time was 26.79 months
(median, 28.0 months; range, 1.0 to 61 months).
Patients whose cause of death remained unknown
were excluded from our study. Clinicopathologic charac-
teristics for these patients including age, sex, hepatitis
history, alpha-fetoprotein (AFP), liver cirrhosis, tumor
number, size, differentiation,s t a g e ,v a s c u l a ri n v a s i o n
and relapse were detailed in Table 1. Tumor differentia-
tion was based on the criteria proposed by Edmonson
and Steiner [16]. Tumor stage was defined according to
American Joint Committee on Cancer/International
Union Against Cancer tumor-node-metastasis (TNM)
classification system [17]. Institute Research Medical
Ethics Committee of Sun Yat-Sen University Cancer
Center granted approval for this study.
RT-PCR
Total RNA was isolated from 8 pairs of HCC tissues
and adjacent non-malignant liver tissues using TRIZOL
reagent (Invitrogen, Carlsbad, CA). RNA was reverse-
transcribed using SuperScript First Strand cDNA System
(Invitrogen, Carlsbad, CA) according to the manufac-
ture’s instructions. PCR was performed as described pre-
viously using specific primers for p300 [18]. The
expression of GAPDH was monitored as a control.
Western blotting analysis
Equal amounts of whole cell and tissue lysates were
resolved by SDS-polyacrylamide gel electrophoresis
(PAGE) and electrotransferred on a polyvinylidene
difluoride (PVDF) membrane (Pall Corp., Port Washing-
ton, NY). The tissues were then incubated with primary
mouse monoclonal antibodies against human anti-p300
(Abcam, Cambridge, MA) at a concentration of 0.5 μg/
ml. The immunoreactive signals were detected with
enhanced chemiluminescence kit (Amersham Bios-
ciences, Uppsala, Sweden). The procedures followed
were conducted in accordance with the manufacturer’s
instructions.
Tissue microarray (TMA) construction
Tissue microarray was constructed as the method
described previously [19]. In brief, formalin-fixed, paraf-
fin-embedded tissue blocks and the corresponding
H&E-stained slides were overlaid for TMA sampling.
The slides were reviewed by a senior pathologist (M-Y.
C.) to determine and mark out representative tumor
areas. Triplicates of 0.6 mm diameter cylinders were
punched from representative tumor areas and from
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tissue block and re-embedded into a recipient paraffin
block at defined position, using a tissue arraying
instrument (Beecher Instruments, Silver Spring, MD).
The TMA block contained 126 HCCs and adjacent non-
malignant liver tissues.
Immunohistochemistry (IHC)
The TMA slides were dried overnight at 37°C,deparaffi-
nized in xylene, rehydrated through graded alcohol,
immersed in 3% hydrogen peroxide for 20 minutes to
block endogenous peroxidase activity, and antigen-
retrieved by pressure cooking for 3 minutes in ethylene-
diamine tetraacetic acid (EDTA) buffer (pH = 8.0). Then
the slides were preincubated with 10% normal goat
serum at room temperature for 30 minutes to reduce
nonspecific reaction. Subsequently, the slides were incu-
bated with mouse monoclonal anti-p300 (Abcam, Cam-
bridge, MA) at a concentration of 3 ng/ml and mouse
monoclonal anti-Ki-67 (Zymed Laboratories Inc., South
San Francisco, CA, 1:100 dilution) for 2 hours at room
temperature. The slides were sequentially incubated
with a secondary antibody (Envision; Dako, Glostrup,
Denmark) for 1 hour at room temperature, and stained
with DAB (3,3-diaminobenzidine). Finally, the sections
were counterstained with Mayer’s hematoxylin, dehy-
drated, and mounted. A negative control was obtained
by replacing the primary antibody with a normal murine
IgG. Known immunostaining positive slides were used
as positive controls.
IHC evaluation
Nuclear immunoreactivity for p300 protein was reported
in semi-quantitative method by evaluating the number
of positive tumor cells over the total number of tumor
cells. Scores were assigned by using 5% increments (0%,
5%, 10%-100%). Expression for p300 was scored by 3
independent pathologists (M. L., R-Z. L. and M-Y. C.)
blinded to clinicopathologic data. Their conclusions
were in complete agreement in 82.1% of the cases,
which identified this scoring method as highly
reproducible.
Selection of Cutoff Score
ROC curve analysis was employed to determine cutoff
score for tumor “high expression” by using the 0,1-
criterion [20]. At the p300 score, the sensitivity and spe-
cificity for each outcome under study was plotted, thus
generating various ROC curves (Figure 1). The score
was selected as the cutoff value, which was closest to
the point with both maximum sensitivity and specificity.
Tumors designated as “low expression” for p300 were
those with scores below or equal to the cutoff value,
while “high expression” tumors were those with scores
above the value. In order to use ROC curve analysis, the
clinicopathologic features were dichotomized: AFP level
(≤ 20 ng/ml or >20 ng/ml), tumor size (≤ 5c mo r> 5
cm), tumor multiplicity (single or multiple), tumor
Table 1 Correlation of p300 expression with patients’
clinicopathologic features in primary hepatocellular
carcinomas
p300 protein
Variable All
cases
Low
expression
High
expression
P
value
a
Age (years) 0.267
≤ 47.7
b 59 28 (47.5%) 31 (52.5%)
>47.7 64 35 (54.7%) 29 (45.3%)
Sex 0.564
Male 107 55 (51.4%) 52 (48.6%)
Female 16 8 (50.0%) 8 (50.0%)
Etiology 0.295
HBV 97 48 (49.5%) 49 (50.5%)
HCV 8 3 (37.5%) 5 (62.5%)
None 18 12 (66.7%) 6 (33.3%)
AFP (ng/ml) 0.000
≤ 20 68 46 (67.6%) 22 (32.4%)
>20 55 17 (30.9%) 38 (69.1%)
Liver cirrhosis 0.334
Yes 87 47 (54.0%) 40 (46.0%)
No 36 16 (44.4%) 20 (55.6%)
Tumor size (cm) 0.000
≤ 5 76 50 (65.8%) 26 (34.2%)
>5 47 13 (27.7%) 34 (72.3%)
Tumor multiplicity 0.012
Single 85 50 (58.8%) 35 (41.2%)
Multiple 38 13 (34.2%) 25 (65.8%)
Differentiation 0.036
Well 15 12 (80.0%) 3 (20.0%)
Moderate 70 36 (51.4%) 34 (48.6%)
Poor 32 14 (43.8%) 18 (56.3%)
Undifferentiated 6 1 (16.7%) 5 (83.3%)
Stage 0.015
I 12 10 (83.3%) 2 (16.7%)
II 49 27 (55.1%) 22 (44.9%)
III 48 23 (47.9%) 25 (52.1%)
IV 14 3 (21.4%) 11 (78.6%)
Vascular invasion 0.130
Yes 55 24 (43.6%) 31 (56.4%)
No 68 39 (57.4%) 29 (42.6%)
Relapse 0.182
Yes 42 18 (42.9%) 24 (57.1%)
No 81 45 (55.6%) 36 (44.4%)
Ki67 expression 0.002
Low 68 44 (64.7%) 24 (35.3%)
High 50 18 (36.0%) 32 (64.0%)
aChi-square test;
bMean age; HBV, hepatitis B virus; HCV, hepatitis B virus; AFP,
alpha-fetoprotein.
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(I + II or III + IV), vascular invasion (absence or pre-
sence), relapse (absence or presence) and survival status
(death due to HCC or censored).
Statistical analysis
Statistical analysis was performed by using the SPSS sta-
tistical software package (standard version 13.0; SPSS,
Chicago, IL). ROC curve analysis was applied to deter-
mine the cutoff score for high expression of p300 and
Ki67. The correlation between p300 expression and clin-
icopathologic features of HCC patients was evaluated by
c
2-test. Univariate and multivariate survival analyses
were performed using the Cox proportional hazards
regression model. Survival curves were obtained with
the Kaplan-Meier method. Predictive accuracy was
quantified using the Harrell concordance index. Differ-
ences were considered significant if the P-value from a
two-tailed test was <0.05.
Results
p300 mRNA expression examined by RT-PCR and p300
protein expression by Western blotting in liver tissues
In this study, the status of expression of p300 mRNA
and p300 protein was further examined by RT-PCR and
Western blotting, respectively, in 8 pairs of fresh HCC
and adjacent non-tumorous liver specimens. The results
showed that a total of 5/8 (62.5%) HCCs was examined
as having up-regulated p300 mRNA expression, when
compared with their adjacent non-malignant liver
Figure 1 ROC curve analysis was created to determine the cutoff score for high expression of p300 protein. The sensitivity and
specificity for each outcome were plotted: AFP level (A.), tumor size (B.), tumor multiplicity (C.), tumor differentiation (D.), clinical stage (E.),
vascular invasion (F.), tumor relapse(G.).
Li et al. Journal of Translational Medicine 2011, 9:5
http://www.translational-medicine.com/content/9/1/5
Page 4 of 11tissues (Figure 2A). Up-regulated expression of p300
protein was observed in 6/8 (75.0%) HCCs, and in each
of the four cases with up-regulated p300 protein, up-
regulated p300 mRNA was observed (Figure 2B).
The expression of p300 in HCC and adjacent non-
malignant liver tissues by IHC
For p300 IHC staining in HCCs and adjacent non-
malignant liver tissues, immunoreactivity was primarily
observed in the nuclei within tumor cells (Figure 2C).
p300 expression could be evaluated informatively in 123
HCCs by the TMA constructed previously. The non-
informative 3 TMA samples included samples with too
few tumor cells (<300 cells per case) and lost samples.
Immunoreactivity of p300 in HCC ranged from 0% to
100% (Figure 2C-2F). According to ROC curve analysis,
expression percentage for p300 above the cutoff value
60% was defined as high expression, while below or
equal to the cutoff value was considered as low expres-
sion. In this study, 16 of the 123 (13.0%) HCC samples
showed completely negative staining of p300. High
expression of p300 could be detected in 60/123 (48.8%)
of HCCs, in 6/87 (6.9%) of adjacent liver tissues with
cirrhosis and in 2/36 (5.6%) of adjacent normal liver tis-
sues without cirrhosis, respectively (P < 0.0001, Fisher’s
exact test).
Selection of cutoff scores for p300 expression
The ROC curves for each clinicopathological parameter
(Figure 1) clearly show the point on the curve closest to
(0.0, 1.0) which maximizes both sensitivity and specifi-
city for the outcome as described in our previous study
[19]. Tumors with scores above the obtained cutoff
value were considered as high p300 expression leading
Figure 2 The mRNA and protein expression of p300 in HCC and adjacent non-malignant liver tissues. A. Up-regulated expression of p300
mRNA was examined by RT-PCR in 3/4 HCC cases, when compared with adjacent non-malignant liver tissues. B. Up-regulated expression of p300
protein was detected by Western blotting in 4/4 HCC cases, when compared with adjacent non-malignant liver tissues. C. High expression of
p300 was observed in a HCC (case 26), in which more than 90% tumor cells revealed positive immunostaining of p300 in nuclei (upper panel,×
100). D. A HCC case (case 81) demonstrated low expression of p300, in which less than 50% of tumor cells showed immunoreactivity of p300
protein in nuclei (upper panel, × 100). E. Nearly negative expression of p300 protein was demonstrated in a HCC case (case 57, upper panel,×
100). F. The adjacent non-malignant liver tissues of HCC case 26 showed nearly negative expression of p300 protein (upper panel, × 100). The
lower panels indicated the higher magnification (× 400) from the area of the box in C., D., E. and F., respectively.
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clinical outcome presence or absence. The correspond-
ing area under the curve (AUC, 95% CI) were collected
and listed in Table 2. Cutoff score for p300 high expres-
sion was determined to be more than 60% carcinoma
cells staining.
Association of p300 expression with HCC patients’
clinicopathological parameters
The high or low expression rates of p300 in HCCs with
respect to several standard clinicopathologic features are
presented in Table 1. The high p300 expression rate was
higher in patients with higher AFP levels (P < 0.0001),
larger tumor size (P < 0.0001), tumor multiplicity (P =
0.012), poorer differentiation (P =0 . 0 3 6 ,T a b l e1 ,F i g u r e
3) and later stage (P = 0.015, Table 1). There was no sig-
nificant correlation between p300 expression and other
clinicopathologic parameters, such as patient age (≤47.7
years vs >47.7 years), sex, hepatitis history, liver cirrhosis,
tumor vascular invasion and relapse (P > 0.05, Table 1).
Relationship between clinicopathologic features, p300
expression, and HCC patients’ survival: Univariate survival
analysis
In order to confirm the representativeness of the HCCs
in our study, we analyzed established prognostic factors
of patients’ survival. Kaplan-Meier analysis demonstrated
a significant impact of well-known clinicopathologic
prognostic parameters, such as serum AFP levels (P <
0.0001), tumor size (P < 0.0001), tumor multiplicity (P <
0.0001), clinical stage (P < 0.0001), vascular invasion (P
<0 . 0 0 0 1 ) ,a n dr e l a p s e( P < 0.0001) on patients’ survival
(Table 3). Assessment of survival in total HCCs revealed
that high expression of p300 was correlated with adverse
disease-specific survival of HCC patients (P = 0.001,
Table 3, Figure 4A). Further analysis was performed
with regard to p300 expression in subsets of patients
with different stages. The results demonstrated as well
that high expression of p300 was a prognostic factor in
HCC patients with stage II (P = 0.007, Figure 4B) and
stage III (P=0.011, Figure 4C). However, it could not
differentiate the outcome of stage I (not reached) or
stage IV patients (P = 0.166, Figure 4D).
Independent prognostic factors of HCC: Multivariate Cox
regression analysis
Since features observed to have a prognostic influence
by univariate analysis may covariate, p300 expression
and those clinicopathologic variables that were signifi-
cant in univariate analysis (i.e., AFP levels, tumor size,
tumor multiplicity, clinical stage, vascular invasion, and
relapse) were further examined in multivariate analysis.
Results showed that high expression of p300 was an
independent prognostic factor for poor patient overall
survival (hazard ratio, 2.077; 95%CI, 1.149-4.112, P =
0.021; Table 3). Of the other parameters, serum AFP
level (P = 0.014) and vascular invasion (P = 0.015) were
evaluated as well independent prognostic factors for
patients’ overall survival.
Prognostic model with p300 expression, AFP level and
vascular invasion
According to the results of our univariate and multivari-
ate analyses, we proposed a new clinicopathologic prog-
nostic model with three poor prognostic factors: p300
expression, AFP level and vascular invasion. Thus, we
designated a high-risk group as the presence of the
three factors (including p300 expression, AFP level and
vascular invasion), an intermediate-risk group as the
presence of two factor (regardless of their identity), and
a low-risk group as the presence of one factor or none.
The model could significantly stratify risk (low, inter-
mediate and high) for overall survival based upon a
combination of p300 and the standard clinicopathologic
features (P < 0.0001, Figure 4E). In addition, application
of Harrell concordance index to the proposed new clini-
copathologic prognostic model showed improved predic-
tive ability when compared with the standard
pathological feature model (c indexes of 0.689 vs 0.648,
respectively).
Correlation between p300 expression and cell
proliferation in HCCs
To address whether or not p300 expression in HCC is
correlated with cell proliferation, the expression of Ki-
67, a widely used cellular proliferation marker, was
investigated by IHC in our HCC cohort. Among the 123
HCCs, in 118 samples, p300 and Ki-67 IHC were exam-
ined successfully and simultaneously. According to the
ROC curve analysis, the cutoff score for Ki67 high
expression was determined to be more than 50% carci-
noma cells staining (data not shown). Using this desig-
nation, high expression of Ki67 was detected in 50/118
(42.4%) HCCs. In addition, a significant positive correla-
tion between expression of p300 and Ki67 was evaluated
Table 2 Area under the curve (AUC) of receiver operating
characteristic curve for each clinicopathologic feature
Variable AUC (95% CI) P value
AFP 0.662 (0.563 to 0.760) 0.002
Tumor size 0.703 (0.606 to 0.800) 0.000
Tumor multiplicity 0.633 (0.525 to 0.741) 0.019
Differentiation 0.634 (0.536 to 0.732) 0.010
Stage 0.609 (0.505 to 0.713) 0.044
Vascular invasion 0.544 (0.441 to 0.647) 0.407
Relapse 0.466 (0.357 to 0.576) 0.543
CI indicates confidence interval.
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with high expression of Ki67 was significantly larger in
carcinomas with a high expression of p300 (32/56 cases,
57.1%) than in those cases with a low expression of
p300 (18/62 cases, 29.0%) (P = 0.002, Table 1).
Discussion
Transcriptional coactivator p300 has the potential to
participate in a variety of cellular functions, such as cell
proliferation and differentiation, senescence and apopto-
sis [7]. Recently several studies have documented an
involvement of p300 in oncogenic processes, such as
lung, colon, prostate, breast cancer and leukemia
[14,21-24]. However, the status of p300 and its potential
prognostic impact on HCC have not been explored so
far. In the present study, we examined the expression
levels of p300 mRNA and p300 protein in HCC tissues
and adjacent non-malignant liver tissues, firstly by RT-
PCR and Western blotting. Our results established that
up-regulated expression of p300 mRNA and p300 pro-
tein was shown in the majority of HCCs, when com-
pared with their adjacent non-malignant liver tissues.
Subsequently, the expression dynamics of p300 protein
was investigated by IHC, using a TMA containing HCC
tissues and adjacent non-malignant liver tissues. Our
IHC results demonstrated that high expression of p300
w a sm o r ef r e q u e n t l yo b s e r v e di nH C Ct i s s u e sw h e n
compared to the adjacent liver tissues with or without
cirrhosis. The expression of p300 in adjacent non-malig-
nant liver tissues with or without cirrhosis was either
absent or at low levels. In contrast, in large number of
our HCC tissues, high expression of p300 was frequently
observed. Previous studies also described that mutation
in p300 gene, accompanied by loss of the other allele,
was observed in certain types of tumors, including col-
orectal, gastric and breast cancers [8,9]. In addition, the
frequency of promoter methylation of p300 gene was
found in 65.8% of HCC [25]. These findings provide evi-
dence that the up-regulation of p300 may play an
important role in tumorigenic process of HCC.
To assess the significance of p300 protein in HCC
and avoid predetermined arbitrary cutpoint, ROC
curve analysis was applied to determine cutoff score
for p300 expression as described in our previous study
[19]. Further correlation analysis revealed that high
expression of p300 in HCCs was correlated with higher
serum AFP levels, larger tumor size, tumor multipli-
city, poorer differentiation and later clinical stage.
Figure 3 The altered expression levels of p300 in HCC tissues by immunohistochemistry. A. and B. represented H&E staining for well-
differentiated HCC (case 43) and poorly-differentiated HCC (case 37), respectively. C. Low expression of p300 was observed in a well-
differentiated HCC case (case 43), in which less than 5% of tumor cells showed immunoreactivity of p300 protein in nuclei (×100). D. High
expression of p300 was demonstrated in the poor-differentiated HCC case (case 37), in which more than 60% carcinoma cells showed
immunoreactivity of p300 in nuclei (×100). Representative sites in HCC tissue with higher (inset, ×400) magnification were shown.
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independent predictor of shortened overall survival as
evidenced by univariate and multivariate analysis. In
addition, stratified survival analysis of HCC accordingly
to clinical stage evaluated p300 expression to be clo-
sely correlated with survival of HCC patients with
stage II or stage III. Since a relatively less cases of
HCC were included in stage I or stage IV, we did not
found statistically significant correlation for these
HCC-subgroups in univariate analysis. Our findings in
this study suggest that expression of p300 in HCC may
facilitate an increased malignant feature and/or worse
prognosis of this tumor. Previous study also suggested that
putative p300 and CREB complex might up-regulate the
H3 and H4 acetylation levels, and then up-regulated
the Hulc expression level which was identified as the
Table 3 Univariate and multivariate analysis of different prognostic factors in 123 patients with hepatocellular
carcinoma (Cox Proportional Hazards Regression)
Univariate analysis Multivariate analysis
Variable All cases HR (95% CI) P value HR (95% CI) P value
Age (years) 0.883
≤47.9
a 59 1.0
>47.9 64 1.044 (0.588-1.853)
Sex 0.746
Male 107 1.153 (0.489-2.717)
Female 16 1.0
Hepatitis history 0.806
Yes 105 0.904 (0.405-2.021)
No 18 1.0
AFP (ng/ml) 0.000 0.014
≤20 68 1.0 1.0
>20 55 5.445 (2.852-10.395) 2.573 (1.209-5.476)
Liver cirrhosis 0.807
Yes 87 1.0
No 36 1.082 (0.578-2.026)
Tumor size (cm) 0.000 0.167
≤5 76 1.0 1.0
>5 47 2.946 (1.640-5.290) 1.595 (0.823-3.090)
Tumor multiplicity 0.000 0.077
Single 85 1.0 1.0
Multiple 38 3.768 (2.108-6.735) 1.790 (0.939-3.414)
Differentiation 0. 099
Well-moderate 85 1.0
Poor-undifferentiated 38 1.642 (0.911-2.958)
Stage 0.000 0.363
I-II 61 1.0 1.0
III -IV 62 5.828 (2.722-12.480) 1.571 (0.593-4.162)
Vascular invasion 0.000 0.015
Yes 55 5.372 (2.724-10.595) 2.724 (1.214-6.113)
No 68 1.0 1.0
Relapse 0.000 0.321
Yes 42 2.885 (1.608-5.174) 1.390 (0.725-2.666)
No 81 1.0 1.0
p300 0.001 0.021
Low expression 63 1.0 1.0
High expression 60 2.792 (1.533-5.087) 2.077 (1.149-4.112)
Ki67 0.089
Low expression 68 1.0
High expression 50 1.661 (0.925-2.982)
aMean age; AFP, alpha-fetoprotein; HR, hazards ratio; CI, confidence interval.
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nation of p300 expression by IHC could be used as an
additional tool in identifying those patients at risk of
HCC progression; p300 expression analysis may also
be useful in optimizing individual HCC therapy man-
agement: favoring a more aggressive regimen in tumors
with a high expression of p300.
Although several characteristics of CBP and p300 sug-
gested that these proteins might serve as tumor suppres-
sors, some studies reported an important role of p300
protein in oncogenic processes [7,26]. In prostate
cancer, p300 expression was shown to be linked to
proliferation and identified as a predictor of progression
of this cancer [14]. In colon carcinoma, overexpression
Figure 4 Kaplan-Meier survival analysis of p300 expression in total patients and subsets of different stage patients with HCC (log-rank
test).A .Total, probability of survival of all patients with HCC: low expression, n = 63; high expression, n = 60. B. Stage II, probability of survival of
stage II patients with HCC: low expression, n = 27; high expression, n = 22. C. Stage III, probability of survival of stage III patients with HCC: low
expression, n = 23; high expression, n = 25. D. Stage IV, probability of survival of stage IV patients with HCC: low expression, n = 3; high
expression, n = 11. E. Comparison of overall survival according to a new combined clinicopathologic prognostic model (including p300, AFP
level and vascular invasion): low risk, n = 70; intermediate risk, n = 29; high risk, n = 24.
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Page 9 of 11of p300 was an indicator of poor prognosis [21]. More-
over, p300 mRNA levels were observed to correlate with
lymph node status in breast cancer [24]. However, p300
protein levels did not show significant correlations with
tumor grade or nodal positivity in other study [27,28].
In the present study, we did observe that high expres-
sion of p300 was associated with an aggressive feature
of HCC and was a strong and independent predictor of
shorter cancer-specific survival. Considering that the
mechanism by which coactivator p300 promotes gene
transcription may vary among gene targets, it is not very
difficult for us to understand that the function of p300
and its underling mechanism(s) to impact cancer pro-
gression may lead to this discrepancy. In addition,
although we observed a positive association of p300
expression and Ki-67 expression (a marker for cell pro-
liferation) in our HCC cohort, the precise signaling
pathway that is ultimately involved in these processes
remains to be investigated. However, our findings sug-
gest a potential important role of p300 in the control of
HCC cell proliferation, an activity that might be respon-
sible, at least in part, for HCC tumorigenesis and/or
progression.
Since advanced pTNM stage and tumor differentiation
are the best-established risk factors for important
aspects affecting the prognosis of patients with HCC
[29]. These 2 parameters, based on specific clinicopatho-
logic features and extent of disease, may have reached
their limits in providing critical information influencing
patient prognosis and treatment strategies. Furthermore,
outcome of patients with same stage following surgery is
substantially different and such large discrepancy has
not been explored [30,31]. Thus, there is a need for new
objective strategies that can effectively distinguish
between patients with favorable and unfavorable prog-
nosis. In this study, our results support the ideas that
p300 expression, as examined by IHC, can identify
patients with HCC that may show aggressive clinical
course and poor outcome. Therefore, evaluation of p300
expression may become a biomarker for predicting
prognosis and rendering a more tailored treatment strat-
egy in patients with HCC. Based on the results, we
propose a new prognostic model with high p300
expression, AFP levels and vascular invasion. This
model including p300 expression can reflect the
aggressive phenotype of HCC. Furthermore, its prog-
nostic significance can be augmented by the elevated
AFP levels and the presence of vascular invasion.
Thus, this combined model may be a useful prognostic
index for HCC.
Conclusions
Our findings provide a basis for the concept that high
expression of p300 may play an important role in the
acquisition of an aggressive phenotype in HCC, suggest-
ing that the expression of p300, as examined by IHC,
will be a promising independent biomarker for shor-
tened survival time of HCC patients. The combined
clinicopathologic prognostic model may become a useful
tool for identifying patients with different clinical
outcomes.
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